Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:KIN

Kindred Biosciences (KIN) Stock Price, News & Analysis

Kindred Biosciences logo

About Kindred Biosciences Stock (NASDAQ:KIN)

Key Stats

Today's Range
$9.24
$9.26
50-Day Range
$9.08
$9.25
52-Week Range
$3.46
$9.28
Volume
178,496 shs
Average Volume
840,890 shs
Market Capitalization
$420.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KIN Stock News Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Kindred Hospital East Greensboro
Japan's Sony terminates $10 bln Zee India merger
European Shares Edge Higher With ECB Meeting In The Spotlight
Earnings Optimism May Contribute To Continued Strength On Wall Street
See More Headlines

KIN Stock Analysis - Frequently Asked Questions

Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to the consensus estimate of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol-Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
8/05/2021
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KIN
Fax
N/A
Employees
63
Year Founded
2013

Profitability

Net Income
$-21,800,000.00
Net Margins
-529.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$42.16 million
Book Value
$1.75 per share

Miscellaneous

Free Float
N/A
Market Cap
$420.52 million
Optionable
Optionable
Beta
1.30

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:KIN) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners